New drug combo shows promise for Tough-to-Treat prostate cancer
NCT ID NCT05005728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safety and tolerability, while also looking at tumor shrinkage, PSA levels, and progression-free survival. The study is completed, and results will help decide if further testing is warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vudalimab (an immunotherapy drug) alone or combined with chemotherapy drugs (carboplatin, cabazitaxel, docetaxel) or targeted therapy (olaparib)
What this could lead to
If successful, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early Phase 2 trial with only 72 participants, so results may not apply to all patients. The drug combinations may cause significant side effects, and the study is completed but results are not yet widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alaska Oncology and Hematology
Anchorage, Alaska, 99508, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
City of Hope
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032, United States
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89148, United States
-
GU Research Network/Urology Cancer Center
Omaha, Nebraska, 68130, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Hospital
Phoenix, Arizona, 85054, United States
-
Montefiore Medical Center
The Bronx, New York, 10461, United States
-
Northwest Cancer Specialists
Tigard, Oregon, 97223, United States
-
Palo Verde Hematology Oncology
Glendale, Arizona, 85304, United States
-
Rocky Mountain Cancer Centers
Lone Tree, Colorado, 80124, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Texas Oncology-Central South
Weslaco, Texas, 78596, United States
-
The University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California, San Diego
San Diego, California, 92093, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas Clinical Research Center
Fairway, Kansas, 66205, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington/Seattle Cancer Care/Alliance
Seattle, Washington, 98109, United States
-
VA Greater Los Angeles
Los Angeles, California, 90064, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
-
XCancer New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico, 87109, United States